KASMEJ
Kastamonu Medical Journal

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

eISSN: 2757-9336
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Determination of hepatitis B and hepatitis C seroprevalence in pregnant women in the Kastamonu region, Turkey
Abstract
Aims: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections during pregnancy have a risk of transmission to the newborn. Therefore, pregnant women are routinely screened for HBV and HCV in many countries. This study aimed to reveal the seroprevalence of HBsAg, anti-HBs, and anti-HCV in pregnant women in the Kastamonu region and to compare the obtained data with the results of studies conducted in Turkey.
Methods: Pregnant women who applied to Kastamonu Training and Research Hospital Microbiology laboratory between January 2022 and January 2023 for HBsAg, anti-HBs, and anti-HCV tests were included in this study. The pregnant women were separated into two groups ?24 and >24 age groups. The tests were performed using the chemiluminescence microparticle immune assay method on the Abbott Architect i2000SR instrument, and the results were evaluated per the manufacturer’s instructions.
Results: HBsAg, anti-HBs, and anti-HCV positivity were 0.5% (n=9/1712), 51.1% (n=874/1712), and 0.1% (n=2/1713), respectively. While there was no significant difference between age groups for HBsAg positivity (p>0.05), anti-HBs positivity was found to be significantly higher in the ?24 age group than in the >24 age group (p=0.002).
Conclusion: The results showed that HBsAg and anti-HCV positivity was lower than in most studies conducted in recent years in Turkey, and anti-HBs positivity was higher than in most studies. It is essential to continue routine HBV and HCV screening in pregnant women’s first follow-up and encourage anti-HBs-negative individuals to be vaccinated against HBV.

Keywords : Anti-HBs, anti-HCV, HBsAg, pregnancy

Download Article


1. Shata MTM, Hetta HF, Sharma Y, Sherman KE. Viral hepatitis inpregnancy. J Viral Hepat. 2022;29(10):844-861.
2. Liang TJ. Hepatitis B: The virus and disease. Hepatology. 2009;49(5Suppl):S13-S21.
3. World Health Organization. Hepatitis B (June 24, 2022). Available from:https://www.who.int/ news-room/fact-sheets/detail/hepatitis-c
4. Centers for Disease Control and Prevention. Viral hepatitis: hepatitis Binformation (March 30, 2022). Available from: https://www.cdc.gov/hepatitis/hbv/bfaq.htm [Accessed April 18, 2023].
5. World Health Organization. Hepatitis C (June 24, 2022). Available from:https://www.who.int/ news-room/fact-sheets/detail/hepatitis-c
6. Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: aconstellation of organ- and non-organ specific autoimmune disorders,B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol.2015;7(3):327-343.
7. Viral Hepatitler Eğitimci Rehberi. T.C Sağlık Bakanlığı Yayın No. 1163,Ankara-2020.
8. Aynıoğlu A, Aynıoğlu Ö, Akar T, Aydın M, Altunok ES. HBsAg, anti-HBsand anti-HCV seropositivity rates among pregnant women attending auniversity hospital in Zonguldak. Viral Hepat J. 2015;21(1):31-34.
9. Dağ ZÖ, Gül S, Işık Y, Tulmaç ÖB, Şimşek Y. Kırıkkale bölgesinde yaşayangebelerde hepatit B ve hepatit C seropozitiflik oranları. Bozok Tıp Derg.2015;5(3):1-4.
10. Bilman FB, Tosun S, Yildiz IE, et al. Prevalence of HBsAg seropositivityduring pregnancy and evaluation of vaccination programs: a multicenterstudy in Turkey. North Clin Istanb. 2021;8(4):359-364
11. Yalçın Bahat P, Turan G, Yüksel Özgör B, Bağcı Çakmak K. Comparisonof hepatitis B, hepatitis C, and HIV seropositivity of Syrian and Turkishpregnant women. Turk J Obstet Gynecol. 2019;16(2):95-99.
12. Sert UY, Engin-Ustun Y, Saygan S, Ozgu-Erdinc AS. Hepatitis B, hepatitisC, and human immunodeficiency virus status in the pregnancy results of atertiary referral center in Turkey. Infect Dis Clin Pract. October 2020. Doi:10.1097/IPC.0000000000000951
13. Çınar Tanrıverdi E, Özkurt Z, Göktuğ Kadıoğlu B, et al. Seroprevalence ofhepatitis B, hepatitis C, and HIV in pregnant women from Eastern Turkey.Turk J Gastroenterol. 2019;30(3):260-265.
14. Kasap B, Öner G, Küçük M, et al. Muğla’daki gebelerin toksoplazma,rubella, sitomegalovirüs ve hepatit prevalansının değerlendirilmesi.Tepecik Eğit ve Araşt Hast Dergisi.2017;27:31-36.
15. Guckan R, Kılınc C, Gozdemir E. HBsAg, anti-HBs, anti-HCV and anti-HIV seroprevalence in pregnant women living. Asian Pacific Journal ofNursing. 2016;3(1):9-12.
16. Alay H, Şahiner M, Göktuğ Kadıoğlu B, Alay RA. Outcomes of passive-active immunoprophylaxis administered to infants of mothers infectedwith Hepatitis B virus in Erzurum, Turkey. JCP. 2019;17(1):110-20.
17. Altuğlu İ, Yaşar M, Ergenoğlu AM, Zeytinoğlu A. Ege Üniversitesi TıpFakültesi Hastanesi’nde gebelerde HBsAg, anti-HIV1/2 ve anti-HCVseroprevalansı. FLORA. 2017;22(3):120-125.
18. Erdoğan A, Yıldız K, Şahin AR, Özden S, Okyay RA. Hepatitis B surfaceantigen seroprevalence of Turkish and foreign patients of reproductive agein 2014-2017. Viral Hepat J. 2020;26(1):5-8.
19. Kale I, Bayik RN, Genc SK. Hepatitis B, hepatitis C and HIV seroprevalencein pregnant women: six years of experience. Turk J Womens. HealthNeonatol. 2020;2(3):89-95.
20. İnci A, Yıldırım D, Seçkin KD, Gedikbaşı A. Analysis of HbsAg positivityrate before and after vaccination in Turkish and Syrian refugee pregnantwomen. J Infect Dev Ctries. 2017;11(10):815-818.
21. Uçkan K, Çeleğen İ, Uçkan T. Evaluation of HBsAg, Anti-HCV, Anti-HIVseroprevalence and perinatal outcomes in pregnant women. Viral Hepat J.2021;27(2):103-108.
22. Cetin S, Cetin M, Turhan E, Dolapcioglu K. Seroprevalence of hepatitisB surface antigen and associated risk factors among pregnant women. JInfect Dev Ctries. 2018;12(10):904-9.
23. Erin R, Kulaksız D, Bayoğlu Tekin Y, Baki Erin K. Trabzon ilinde gebelerdehepatit B, hepatit C, HIV ve RPR seropozitifliği. GUJHS. 2021;10(3):507-512.
24. Karbancıoğlu Cantürk F, Dağlı SS, Cantürk M. Kırşehir ilindeki Suriye’limültecilerin perinatal sonuçlarının değerlendirilmesi. Ahi Evran Med J.2019;1(3):6-11.
25. Şahin M, Zencir M, Gözübüyük AA, Pektaş BA. Seroprevalence ofhepatitis B surface antigen, anti-hepatitis B surface and anti-hepatitis Cvirus among pregnant women residing in Şırnak province. Viral Hepat J.2018;24(1):7-11.
26. Mutlu S, Yılmaz Ş. Türk ve mülteci gebelerde HBsAg, anti-HBs, anti-HCVve anti-HIV seropozitifliklerinin karşılaştırılması. DÜ Sağlık Bil Enst Derg.2021;11(1):21-4.
27. Öner SZ, Kalıpcı İ, Okur A. Gebelerde HBsAg ve Anti-HCV seroprevalansıile hepatit B bağışıklığının değerlendirilmesi: tanımlayıcı çalışma. Med JWest Black Sea. 2021;5(2):156-161.
28. Beyazgül B, Öztürk E, Koruk İ, Koruk F. Bir doğum hastanesinde HBsAgtarama testi ve hepatit B’yi önleme uygulamalarının değerlendirilmesi.ADYÜ Sağlık Bilimleri Derg. 2020;6(3):332-337.
29. Aksin Ş, Çim N, Andan C, Tunç Ş, Göklü MR. Comparison of obstetricand infectious results among Syrian pregnant women. Ann Clin Anal Med.2021;12(5):501-505.
30. Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis Bvirus. Can J Infect Dis Med Microbiol. 2005;16(2):65-72.
31. Interim guidance for country validation of viral hepatitis elimination.Geneva: World HealthOrganization; 2021. Licence: CC BY-NC-SA 3.0IGO.
32. Simavli S, Ozlu T, Kucukbayrak B. Age specific prevalence of hepatitis Band hepatitis C among pregnant women in the northwestern region ofTurkey. Indian J Gastroenterol. 2014;33(3):293-294.
33. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: a review of itsimmunogenicity and protective efficacy against hepatitis B. BioDrugs.1998;10(2):137-158.
34. Centers for Disease Control and Prevention. Interpretation of hepatitis Bserologic test results. Available from: https://www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf
35. Gülcü S, Arslan S. Çocuklarda aşı uygulamaları: güncel bir gözdengeçirme. DÜ Sağlık Bil Enst Derg. 2018;8(1):34-43.
36. Walewska-Zielecka B, Religioni U, Juszczyk G, et al. Anti-hepatitis C virusseroprevalence in the working age population in Poland, 2004 to 2014.Euro Surveill. 2017;22(2):30441.
37. Centers for Disease Control and Prevention. Testing recommendationsfor Hepatitis C virus infection (July 29, 2022). Available from: https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm
38. Altınbas S, Holmes JA, Altınbas A. Hepatitis C virus infection inpregnancy: an update. Gastroenterol Nurs. 2020;43(1):12-21.
39. Tunç N. Chronic Hepatitis C prevalence and physician awareness inSoutheastern Turkey. Viral Hepat J. 2019;25(3):101-104.
Article available in :
Volume 3, Issue 2, 2023
Page : 80-84
https://doi.org/10.51271/KMJ-0103
Article Information
Received : 19 Nis 2023
Accepted : 12 May 2023
Published : 26 Haz 2023
Corresponding Author :

Enis Fuat Tüfekci: Kastamonu University, Faculty of Medicine, Department of Medical Microbiology, Kastamonu, Türkiye

[email protected]
Citation : Tüfekci EF, Çalışır B, Yaşar Duman M, Kılınç Ç. Determination of hepatitis B and hepatitis C seroprevalence in pregnant women in the Kastamonu region, Turkey. Kastamonu Med J. 2023;3(2):80-84

Read: 456
Cited: 0
Download : 324
_Footer